RecruitingPhase 4NCT07666984

The Effect of Neostigmine and Sugammadex on the Optic Nerve Sheath Diameter

Comparison of the Effects of Neostigmine and Sugammadex on the Optic Nerve Sheath Diameter During the Postoperative Extubation Period


Sponsor

Cukurova University

Enrollment

86 participants

Start Date

Jun 4, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study will compare how two drugs, sugammadex and neostigmine-used to reverse muscle relaxation after surgery-affect the size of the optic nerve sheath (the nerve behind the eye) as patients wake up and have their breathing tubes removed. It will also examine the relationship between changes in blood pressure and heart rate during this time and these measurements. This study will be conducted on 86 healthy patients aged 18-65 who will undergo planned surgery at the Çukurova University Faculty of Medicine, Department of Anesthesiology and Reanimation. Patients will be randomly divided into two groups: the sugammadex group and the neostigmine group. All patients will receive standard general anesthesia and rocuronium to relax their muscles. At the end of the surgery, to reverse this effect, patients will be given either sugammadex or a mix of neostigmine and atropine. Group S will receive 2 mg sugammadex per kg, while Group N will receive 0.05 mg neostigmine and 0.02 mg atropine per kg. The width of the optic nerve sheath will be measured by ultrasound 5 minutes after the breathing tube is inserted, 5 minutes before the tube is removed, and 5 minutes after it is removed. Additionally, blood pressure, heart rate, and any complications during the surgery will be tracked and compared between the groups.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria3

  • With an ASA physical status of 1-2
  • Patients scheduled for elective surgery
  • Patients willing to participate in the study

Exclusion Criteria8

  • Patients with heart, liver, kidney, or respiratory failure
  • Brain tumors, hemorrhages, or aneurysms
  • Patients who have undergone eye, cardiovascular, or neurosurgery
  • Eye or neurological diseases or increased intracranial pressure
  • Laparoscopic surgeries
  • Cases not in the supine position
  • Allergy to the medications used
  • Patients who did not provide informed consent to participate in the study.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSugammadex 2 mg/kg

Intravenous bolus injection

DRUGNeostigmine + Atropine

Intravenous bolus injection


Locations(1)

Cukurova University Faculty of Medicine

Adana, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07666984


Related Trials